Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.06 · Revenue $1.08M · 3 analysts
Est. EPS $-0.07 · Revenue $1.02M · 3 analysts
Est. EPS $-0.26 · Revenue $4.74M · 3 analysts
Est. EPS $-0.08 · Revenue $1.70M · 1 analysts
EPS $-0.05 · Revenue $1.37M
EPS $-0.05 · Revenue $1.48M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $4.4M | +8.8% | -2.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-67.8M | -25.5% | -29.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +45.9% | -10.9% | 0.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1425.7% | -5.6% | +5.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -1537.4% | -15.3% | -33.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-57.1M | -25.5% | +42.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1295.0% | -15.3% | +40.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -272.4% | -348.4% | -192.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.06x | -63.0% | -56.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $43.5M | -47.2% | +118.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.23 vs -0.23 | -0.5% | -0.07 vs -0.06 | -16.7% |
| Revenue Surprise | $4.4M vs $5.6M | -21.2% | $1.5M vs $1.1M | +38.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | Johnson-Greene Treerita Essalima | officer: Chief Financial Officer | Common Stock | A | 21,000 | $1.23 |
| Jun 11, 2026 | Kompella Uday | director | Stock Option (Right to Buy) | A | 170,100 | $1.22 |
| Jun 11, 2026 | Chandrasekhar Satishchandran | director | Stock Option (Right to Buy) | A | 170,100 | $1.22 |
| Jun 11, 2026 | Castillo Kirsten | director | Stock Option (Right to Buy) | A | 170,100 | $1.22 |
| Jun 11, 2026 | Zhang Junge | director | Stock Option (Right to Buy) | A | 170,100 | $1.22 |
Operator: Good morning, and welcome to Ocugen's Second Quarter 2026 Financial Results and Business Update. [Operator Instructions] I will now turn the call over to Chris Clark, Ocugen's Head of Communications. You may begin. Chris Clark: Thank you, Operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's Chairman, CEO, and Co-Founder, who will provide a business update and an overview of our clinical and operational progress; Rita Johnson-Greene, our Chief Financial Officer, is also on the call to provide a financial update for the quarter ended June 30, 2026; Abhi Gupta, Executive Vice President of Commercial and Business Development; and Dr. Mohamed Genead, who joined Ocugen as Chief Medical Officer in June, will be available to answer questions following the presentation. This morning we issued a press release covering our business and operational highlights for the second quarter of 2026. We encourage listeners to review the press release, which is available on our website at ocugen.com. A replay of this call, along with the accompanying slide presentation, will be available on the Investors section of the Ocugen website. Please note that certain statements made during today's discussion may be forward-looking in nature, including those related to our clinical development pipeline, regulatory time lines, commercialization strategy, and financial information, and our anticipated cash runway. These statements reflect management's current expectations and are inherently subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied. We encourage you to review our filings with the Securities and Exchange Commission, including the risk factors detailed therein, for a more comprehensive understanding of these potential risks. Finally, Ocugen's quarterly report on Form 10-Q covering the second quarter of 2026 will be filed today. I will now turn the call over to Dr. Musunuri. Shankar Musunuri: Thank you, Chris, and good morning, everyone. The second quarter was a defining one for Ocugen. The FDA cleared our Phase 3 trial for OCU410 to initiate dosing in geographic atrophy patients and granted RMAT designation for the program. We signed a binding term sheet with Roots Pharmaceutical to negotiate an exclusive license for OCU400 in retinitis pigmentosa across the Middle East and North Africa, MENA region. And from the closing of $130 million convertible notes financing, we extended our cash runway into 2028, now able to support all 3 of our late-stage programs. Before I walk through the quarter, I want to step back, because Ocugen's potential is worth putting into context. For more than a decade, gene therapy in ophthalmology has been confined to a single gene, a single mutation and a single small patient population. Our modified gene therapy platform takes a fundamentally different approach. Rather than targeting individual …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Shankar Musunuri | Co-Founder, Chief Executive Officer & Chairman | USD 1,261,506 | — | 1964 | Active |
Arun Upadhyay | Chief Scientific Officer and Head of Research & Development | USD 703,751 | — | 1982 | Active |
Mohamed Genead | Chief Medical Officer | USD 644,027 | — | — | Active |
Vijay Tammara | Chief Development Officer | USD 490,915 | — | 1960 | Active |
Durgaprasad Annavajjula | Vice President, Head of Program Management & Chief of Staff | — | — | — | Active |
Chris Clark | Head of Corporation Communications | — | Male | — | Active |
Jyothy Pillai | Vice President & Head of Regulatory & Quality | — | Female | — | Active |
Kristen Craft | Head of People & Culture | — | Female | — | Active |
Rita Johnson-Greene | CFO & Principal Accounting Officer | — | Female | 1977 | Active |
Tiffany Hamilton | AVP & Head of Corporate Communications | — | Female | — | Active |
Paul Staid | Executive Vice President of Operations | — | Male | — | Active |
John Kouch | General Counsel | — | — | — | Active |
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month
Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
